This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sahin, U. Articles by Türeci, O. Search for Related Content PubMed PubMed Citation Articles by Sahin, U. Articles by Türeci, O.

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development

Authors' Affiliations: ¹ Ganymed Pharmaceuticals; ² Department of Internal Medicine III, Division of Translational and Experimental Oncology, Johannes Gutenberg University, Mainz, Germany; ³ Department of Pathology, Algemeen Stedelijk Ziekenhuis Aalst, Aalst, Belgium; and ⁴ Department of Pathology, Hospital Bamberg, Bamberg, Germany

Requests for reprints: Ugur Sahin, Department of Internal Medicine III, Division of Translational and Experimental Oncology, Johannes Gutenberg University, Obere Zahlbacherstrasse 63, Mainz 55131, Germany. Phone: 49-6131-3933394; Fax: 49-6131-3933343; E-mail: sahin{at}uni-mainz.de.

Purpose: Antibody-based cancer therapies have emerged as the most promising therapeutics in oncology. The purpose of this study was to discover novel targets for therapeutic antibodies in solid cancer.

Experimental Design: We combined data mining and wet-bench experiments to identify strictly gastrocyte lineage–specific cell surface molecules and to validate them as therapeutic antibody targets.

Results: We identified isoform 2 of the tight junction molecule claudin-18 (CLDN18.2) as a highly selective cell lineage marker. Its expression in normal tissues is strictly confined to differentiated epithelial cells of the gastric mucosa, but it is absent from the gastric stem cell zone. CLDN18.2 is retained on malignant transformation and is expressed in a significant proportion of primary gastric cancers and the metastases thereof. In addition to its orthotopic expression, we found frequent ectopic activation of CLDN18.2 in pancreatic, esophageal, ovarian, and lung tumors, correlating with distinct histologic subtypes. The activation of CLDN18.2 depends on the binding of the transcription factor cyclic AMP–responsive element binding protein to its unmethylated consensus site. Most importantly, we were able to raise monoclonal antibodies that bind to CLDN18.2 but not to its lung-specific splice variant and recognize the antigen on the surface of cancer cells.

Conclusions: Its highly restricted expression pattern in normal tissues, its frequent ectopic activation in a diversity of human cancers, and the ability to specifically target this molecule at the cell surface of tumor cells qualify CLDN18.2 as a novel, highly attractive pan-cancer target for the antibody therapy of epithelial tumors.